Bioequivalence and Bioavailability Forum

SMA ☆ Europe, 2024-01-16 10:51 (869 d 13:54 ago) (edited on 2024-01-16 11:07) Posting: # 23828 Views: 5,895	New EMA product specific guidance (PSG) [BE/BA News] Post reply
	Dear all EMA has published two new PSGs: Azacitidine powder for suspension for injection 25 mg/ml product-specific bioequivalence guidance (here) Paliperidone palmitate depot suspension for injection (every 3 months) 175, 263, 350 and 525 mg product-specific bioequivalence guidance (here) Consultations open until 2024-04-30

dshah
★★

India,
2024-01-17 11:12
(868 d 13:33 ago)

@ SMA
Posting: # 23830
Views: 4,434

New EMA product specific guidance (PSG)

Post reply

Thanks SMA for sharing.

Dear all, In Azacitidine powder for suspension for injection PSG, I am having a small question.

For biowaiver it is mentioned- "Equivalent particle size distribution as demonstrated by showing average equivalence for D10, D50, D90 and span within an acceptance range of 15% for the ratio of geometric means between test and reference products (i.e., 85.00–117.64%)."
But it also mentions: "At least 3 batches of the test and reference product should be included in the comparability studies. More batches may be needed in case of higher variability of the reference product results."

So in case of higher variability in reference product result for PSD, the ratio should be limited to 85.00–117.64%?

Regards,
Divyen

New EMA product specific guidance (PSG) [BE/BA News]

New EMA product specific guidance (PSG)